Global Systemic Sclerosis Market is segmented By Type (Limited, Diffuse), By Drug Type (Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, Phosphodiesterase 5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Market Overview

The Global Systemic Sclerosis Market is expected to grow at a CAGR of 6.0% during the forecasting period (2022-2029).

Systemic sclerosis (SSc) is a systemic connective tissue disease of unknown etiology that affects the skin, blood vessels, muscles, joints, and a variety of internal organs, such as the digestive tract, heart, lungs, and kidneys.
The global Systemic sclerosis treatment market is estimated to reach USD 1.4 million by 2024.

Primary market drivers include increased use of expensive biologics, the rise in clinical trials for systemic sclerosis, high acceptance of new therapies by patients, and new drug approvals.
However, delay in diagnosis and lack of safe and effective treatments will restrain the market growth.

The Global Systemic sclerosis market report segments the market by type, drug type, and region.
Based on the extent of skin involvement, the market is segmented into Limited cutaneous systemic sclerosis (lcSSc), or limited scleroderma, and Diffuse cutaneous systemic sclerosis (dcSSc), or diffuse scleroderma.
Limited cutaneous systemic sclerosis is the more common type of SSc.
Based on drug type, the market is segmented into Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, and ACE Inhibitors.
Regarding the drug category, the segment of immunosuppressive agents is expected to retain dominance over the forecast period.
Regionally, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
North America will dominate the market. The US has an annual incidence of about 20 cases per 1 million adults.

The report profiles the following companies of Systemic sclerosis market – Actelion, Roche/Genentech, BMS, Allergan, GSK, Biogen, Novartis, Teva, MedImmune, Celgene, Chugai, ASTA, Aspen, Pfizer, Eli Lilly, Bayer, and many more.

By Type

By Drug Type

By Region